BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 20353833)

  • 21. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
    Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation.
    Wirk B; Klumpp TR; Ulicny J; Herman JH; Gajewski JL; Martin ME; Emmons RV; Mangan KF
    Transfusion; 2008 Jan; 48(1):163-8. PubMed ID: 17900280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation.
    Milosevic S; Bachnick B; Karim K; Bornkamm GW; Witter K; Gerbitz A; Mautner J; Behrends U
    Transplantation; 2010 Nov; 90(9):1030-5. PubMed ID: 20802400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
    van der Straaten HM; Paquay MM; Tilanus MG; van Geloven N; Verdonck LF; Huisman C
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1231-6. PubMed ID: 21215810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation.
    Danzer M; Polin H; Pröll J; Haunschmid R; Hofer K; Stabentheiner S; Hackl C; Kasparu H; König J; Hauser H; Binder M; Weiss R; Gabriel C; Krieger O
    Transplantation; 2009 Aug; 88(4):528-32. PubMed ID: 19696636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
    Willems E; Baron F; Seidel L; Frère P; Fillet G; Beguin Y
    Bone Marrow Transplant; 2010 Apr; 45(4):689-93. PubMed ID: 19718063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras.
    Brochu S; Baron C; Hétu F; Roy DC; Perreault C
    J Immunol; 1995 Dec; 155(11):5104-14. PubMed ID: 7594519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; Ruiz-Argüelles A; González-Llano O; Cantú OG; Jaime-Pérez JC
    Am J Hematol; 2001 Apr; 66(4):241-4. PubMed ID: 11279633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
    Chao NJ
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.
    Wang W; Huang H; Halagan M; Vierra-Green C; Heuer M; Brelsford JE; Haagenson M; Scheuermann RH; Telenti A; Biggs W; Pearson NM; Udell J; Spellman S; Maiers M; Kennedy CJ
    Blood Adv; 2018 Oct; 2(19):2419-2429. PubMed ID: 30262602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.
    Van Bergen CA; Rutten CE; Van Der Meijden ED; Van Luxemburg-Heijs SA; Lurvink EG; Houwing-Duistermaat JJ; Kester MG; Mulder A; Willemze R; Falkenburg JH; Griffioen M
    Cancer Res; 2010 Nov; 70(22):9073-83. PubMed ID: 21062987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.